A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic arm...

Full description

Bibliographic Details
Main Authors:	K M Prasanna Kumar, Sujoy Ghosh, William Canovatchel, Nishant Garodia, Sujith Rajashekar
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2017-01-01
Series:	Indian Journal of Endocrinology and Metabolism
Subjects:	Canagliflozin glycated hemoglobin hypoglycemic agents pleiotropic benefits sodium-glucose cotransporter 2 inhibitor type 2 diabetes mellitus
Online Access:	http://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=1;spage=196;epage=209;aulast=Prasanna

Similar Items

Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020
by: Yudai Uehira, et al.
Published: (2022-06-01)

Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
by: Vishal Gupta, et al.
Published: (2017-01-01)

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
by: Ryo Nishinarita, et al.
Published: (2021-01-01)

Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
by: Shuqin Du, et al.
Published: (2022-10-01)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
by: Kiyohiko Takahashi, et al.
Published: (2019-03-01)

Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
by: Xue Yang, et al.
Published: (2023-10-01)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
by: Masafumi Fukuda, et al.
Published: (2020-01-01)

The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following <i>In Vitro</i> Vascular Ischemia/Reperfusion Injury in Rats
by: Sevil Korkmaz-Icöz, et al.
Published: (2021-07-01)

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
by: Alex Ali Sayour, et al.
Published: (2019-04-01)

EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
by: Rishad Ahmed, et al.
Published: (2017-01-01)

Use of Continuous Glucose Monitoring in Patient with Coronary Artery Disease and Type 2 Diabetes Mellitus: Case Report
by: Georgy B. Mankovsky, et al.
Published: (2022-03-01)

Proteomic Profiling of SGLT-2 Inhibitor Canagliflozin in a Swine Model of Chronic Myocardial Ischemia
by: Dwight D. Harris, et al.
Published: (2024-03-01)

Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia
by: Sharif A. Sabe, et al.
Published: (2023-01-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study
by: Sammar Fathy Elhabal, et al.
Published: (2023-12-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model
by: Chang Chu, et al.
Published: (2022-09-01)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
by: Davies MJ, et al.
Published: (2017-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
by: Manash P Baruah, et al.
Published: (2016-01-01)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
by: Aika Miya, et al.
Published: (2021-08-01)

Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation
by: Luxun Tang, et al.
Published: (2023-12-01)

Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout
by: T. S. Panevin, et al.
Published: (2020-06-01)

Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
by: Juan J. Gorgojo-Martinez, et al.
Published: (2023-06-01)

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
by: Mobin Mohammadtabar, et al.
Published: (2023-03-01)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
by: Kyu Yong Cho, et al.
Published: (2021-08-01)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

Blood glucose levels and bodyweight change after dapagliflozin administration
by: Hyunah Kim, et al.
Published: (2021-09-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Candidemia Following Ureteric Stent Placement in a Patient With Type 2 Diabetes Treated With Canagliflozin
by: Rishi Raj, et al.
Published: (2019-01-01)

Analysis of the regional pharmaceutical market of hypoglycemic drugs of oral administration
by: Orlova T.S., et al.
Published: (2017-06-01)

Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis
by: Kirandeep Kaur, et al.
Published: (2015-01-01)

SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes
by: Natalia Stepanova
Published: (2024-01-01)

Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats
by: Yukishige Kimura, et al.
Published: (2019-07-01)

Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
by: Mohammed Moutaz Nakhal, et al.
Published: (2022-10-01)

Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study
by: Pankaj Aneja, et al.
Published: (2019-01-01)

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
by: Sheng‐Nan Chang, et al.
Published: (2023-05-01)

Modern approaches to the treatment of type 2 diabetes mellitus
by: T. V. Morgunova, et al.
Published: (2018-03-01)

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01)

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial
by: Atsushi Tanaka, et al.
Published: (2022-12-01)